David Meek Sells 1,993 Shares of uniQure (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) Director David Meek sold 1,993 shares of uniQure stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $27.06, for a total transaction of $53,930.58. Following the sale, the director owned 39,747 shares in the company, valued at approximately $1,075,553.82. The trade was a 4.77% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

uniQure Trading Up 2.8%

QURE stock opened at $27.57 on Friday. The firm has a fifty day moving average price of $22.52 and a 200 day moving average price of $21.80. uniQure N.V. has a fifty-two week low of $8.73 and a fifty-two week high of $71.50. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40. The firm has a market cap of $1.74 billion, a PE ratio of -7.92 and a beta of 0.98.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The firm had revenue of $3.56 million during the quarter, compared to analyst estimates of $5.21 million. Sell-side analysts anticipate that uniQure N.V. will post -3.64 earnings per share for the current fiscal year.

Key Headlines Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Negative Sentiment: A cluster of insiders sold shares in recent filings, including directors Robert Gut, Madhavan Balachandran, Rachelle Suzanne Jacques, Jack Kaye, Leonard E. Post, Jeremy P. Springhorn, and David D. Meek, along with insider Kylie O’keefe. The transactions totaled a meaningful reduction in ownership across the group, increasing focus on insider confidence. Article: UniQure Rocked by Wave of High-Level Insider Stock Sales
• Neutral Sentiment: Several of the sales were made under pre-arranged Rule 10b5-1 trading plans, which can lessen the bearish signal because the trades may have been scheduled in advance rather than reflecting a sudden change in outlook.
• Neutral Sentiment: The stock has already been trending above its 50-day and 200-day moving averages, so some of the selling may simply reflect profit-taking after a strong move rather than a deterioration in the company’s fundamentals.

Wall Street Analysts Forecast Growth

Several research firms have commented on QURE. Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. The Goldman Sachs Group lifted their price objective on shares of uniQure from $9.00 to $10.00 and gave the stock a “neutral” rating in a research note on Monday, April 20th. Leerink Partners reaffirmed an “outperform” rating and set a $35.00 price objective on shares of uniQure in a research note on Monday, March 2nd. Sanford C. Bernstein lowered shares of uniQure to a “market perform” rating in a research note on Tuesday, March 3rd. Finally, Mizuho raised shares of uniQure from a “neutral” rating to an “outperform” rating and lifted their price objective for the stock from $12.00 to $35.00 in a research note on Wednesday, March 11th. Ten analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $42.83.

Institutional Trading of uniQure

Large investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of uniQure by 15.7% during the third quarter. Vanguard Group Inc. now owns 1,125,108 shares of the biotechnology company’s stock valued at $65,673,000 after purchasing an additional 152,417 shares during the period. Aberdeen Group plc raised its holdings in shares of uniQure by 6.9% in the third quarter. Aberdeen Group plc now owns 2,939,743 shares of the biotechnology company’s stock valued at $171,593,000 after acquiring an additional 189,029 shares in the last quarter. Quinn Opportunity Partners LLC bought a new stake in shares of uniQure in the third quarter valued at about $6,281,000. Farallon Capital Management LLC raised its holdings in shares of uniQure by 3,935.7% in the third quarter. Farallon Capital Management LLC now owns 565,000 shares of the biotechnology company’s stock valued at $32,979,000 after acquiring an additional 551,000 shares in the last quarter. Finally, Boone Capital Management LLC bought a new stake in shares of uniQure in the third quarter valued at about $8,599,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.